| Similar Articles |
|---|
 |
Bio-IT World
August 13, 2002
Kevin Davies |
Curtailing the Cancerous Cell The highly touted drug Gleevec unleashed new hope in the battle against cancer. Now a group of new drugs, working on the same principle, are showing even greater promise in treating leukemia.   |
Managed Care
May 2004
Thomas Morrow |
New Agents Regulating Tyrosine Kinase Can Be Used Against Several Cancers When traditional therapies fail in cancer treatment, turning off a chemical switch may offer hope to the hopeless. |
Chemistry World
July 2010 |
Column: In the pipeline Derek Lowe ponders the possibility of phosphatase inhibitors |
Pharmaceutical Executive
July 1, 2011
Dickmeyer & Rosenbeck |
From Rut to Racetrack Can the pharmaceutical industry deliver on its objective to make cancer a curable, chronic condition? |
Managed Care
November 2004
Thomas Morrow |
Pharmacogenetic, Pharmacogenomic Testing Rapidly Gaining Acceptance New tests will allow better determination of which therapies will work on which patients, thus improving care and reducing outlays for failed therapies. |
Wired
August 2003
Jennifer Kahn |
The End of Cancer (As we Know it) Diagnosis. Chemotherapy. Radiation. Slow painful death. No more. A new era of cancer treatment is dawning. Meet three scientists who are using the revelations of the Human Genome Project to reshape medicine. |
The Motley Fool
October 27, 2010
Ralph Casale |
Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment. |
Chemistry World
January 21, 2013
Michael Parkin |
Flow synthesis for anticancer drug UK chemists have used a combination of flow chemistry methods with solid-supported scavengers and reagents to synthesize the active pharmaceutical ingredient, imatinib, of the anticancer drug Gleevec. |
